Fig 1.
PRISMA flow diagram for selected studies included in the systematic review and meta-analysis.
Fig 2.
Risk of bias summary across randomized controlled trials using version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) [19].
(A). RoB2 risk of bias summary of randomized control trials traffic light; (B). Risk of bias graph across randomized controlled trials.
Fig 3.
Summary across the Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I) tool [19].
(A). ROBINS-I risk of bias summary of non-randomized control trials traffic light; (B). ROBINS-I risk bias graph across non-randomized controlled trials.
Table 1.
Clinical and environmental factors.
Table 2.
Host and parasite factors related to recurrences and visual acuity.
Table 3.
Treatment-related factors influencing reactivations and visual acuity outcomes in OT.
Fig 4.
Frequency of recurrence segmented by continent.
Fig 5.
Frequency of visual impairment and blindness of OT.
(A).Visual impairment, (B). Blindness.
Fig 6.
(A). Laterality, (B). Localization; (C). Sex; (D). Number of lesions.
Fig 7.
(A). Localization, (B). Recurrences.
Fig 8.
Effect of the treatment on the recurrences and visual factor.
(A). Any scheme of P+Sdz vs Intravitreal clindamycin + dimethazone, (B). Any scheme of P+Sdz vs Subconjunctival clindamycin, (C). Any scheme of TMP/SMX vs Any scheme of P+Sdz.
Fig 9.
Effect of the prophylaxis on the recurrences.
(A). Reduction in recurrence with prophylaxis in the first year, (B). Reduction in recurrence with prophylaxis in the second year.
Table 4.
Prophylaxis scheme in OT.